Cargando…

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964030/ http://dx.doi.org/10.2147/COPD.S60928

Ejemplares similares

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]
Publicado: (2015)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
Publicado: (2017)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
por: Wang, Chen, et al.
Publicado: (2015)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

The Association Between Cognitive Functions and Psychological Factors in Patients with Severe COPD [Corrigendum]
Publicado: (2023)

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]
Publicado: (2019)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Publicado: (2015)

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Publicado: (2014)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
Publicado: (2019)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

COPD and glycopyrronium responsiveness assessment: An appraisal
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2023)

Corrigendum to “Recommendations for Diagnosis and Management of Osteoporosis in COPD Men”
por: Mazokopakis, Elias E., et al.
Publicado: (2017)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]
Publicado: (2019)

Nasal high-flow in acute hypercapnic exacerbation of COPD [Corrigendum]
Publicado: (2019)

Repetitive Saliva Swallowing Test Predicts COPD Exacerbation [Corrigendum]
Publicado: (2021)

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial
por: Frith, Peter A, et al.
Publicado: (2015)

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study [Corrigendum]
Publicado: (2020)

Corrigendum to “Zeaxanthin: Review of Toxicological Data and Acceptable Daily Intake”
por: Edwards, James A., et al.
Publicado: (2019)

Once We Find Grade III Meconium Stained Amniotic Fluid, Must We Act as Early as Possible? [Corrigendum]
Publicado: (2023)

Predicting frequent COPD exacerbations using primary care data [Corrigendum]
Publicado: (2018)

The Relationship Between Morning Symptoms and the Risk of Future Exacerbations in COPD [Corrigendum]
Publicado: (2021)

Image-Enhanced Bronchoscopic Evaluation of Bronchial Mucosal Microvasculature in COPD [Corrigendum]
Publicado: (2022)

Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease [Corrigendum]
Publicado: (2022)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE [Corrigendum]
Publicado: (2016)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
por: Molino, Antonio, et al.
Publicado: (2017)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
por: Buhl, Roland, et al.
Publicado: (2015)

Reduced Variability of Endurance Time in New Protocols for Exercise Tests in COPD [Corrigendum]
Publicado: (2021)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cago7m27ctneamk4855bedd75a